Otsuka And Lundbeck Submit SNDA For FDA Review Of Brexpiprazole And Sertraline Combination As Potential Treatment For Ptsd
09/04/2024 07:02
April 9 (Reuters) - Otsuka Holdings Co Ltd 4578.T :
* OTSUKA HOLDINGS CO LTD: OTSUKA AND LUNDBECK SUBMIT SNDA
FOR FDA
REVIEW OF BREXPIPRAZOLE AND SERTRALINE COMBINATION AS POTENTIAL
TREATMENT FOR PTSD
Source text for Eikon: ID:nTSpi8a94e
Further company coverage: 4578.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on H Lundbeck A/S
See all newsEurope Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Brief: H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options